Advertisement
Screener

CONTEXT THERAPEUTICS INC. (CNTX) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price

1.4 / 5 stars · 10/35 Roast Me

CONTEXT THERAPEUTICS INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price

CONTEXT THERAPEUTICS INC. (CNTX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $1.46 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-05

  • CONTEXT THERAPEUTICS INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.25.
  • CONTEXT THERAPEUTICS INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.26.
  • CONTEXT THERAPEUTICS INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.00.
  • CONTEXT THERAPEUTICS INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $1.73, a 33.08% increase from fiscal 2024.
  • CONTEXT THERAPEUTICS INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $1.30, a 76.99% decline from fiscal 2023.
  • CONTEXT THERAPEUTICS INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $5.65, a 124.21% increase from fiscal 2022.
  • CONTEXT THERAPEUTICS INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $2.52.
Period endShare-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month
2026-06-30$1.46
10-Q · filed 2026-08-05
2026-03-31$1.25
10-Q · filed 2026-05-06
2025-12-31$1.73
10-K · filed 2026-03-23
2025-09-30$1.73
10-Q · filed 2025-11-05
2025-06-30$1.74
10-Q · filed 2025-08-06
2024-12-31$1.30
10-K · filed 2025-03-20
2024-09-30$1.30
10-Q · filed 2024-11-06
2024-06-30$1.30
10-Q · filed 2024-08-07
2024-03-31$1.26
10-Q · filed 2024-05-08
2023-12-31$5.65
10-K · filed 2024-03-21
2023-09-30$1.40
10-Q · filed 2023-11-09
2023-03-31$0.00
10-Q · filed 2023-05-10
2022-12-31$2.52
10-K · filed 2023-03-22
2022-09-30$2.52
10-Q · filed 2022-11-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
ROCKWELL MEDICAL, INC. (RMTI)United States$0.035B
Propanc Biopharma, Inc. (PPCB)$0.032B-0.13
CHINA PHARMA HOLDINGS, INC. (CPHI)$0.032B
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30
NANOVIRICIDES, INC. (NNVC)United States$0.031B
Seres Therapeutics, Inc. (MCRB)United States$0.036B-3.45
BeyondSpring Inc. (BYSI)United States$0.031B-10.95
BriaCell Therapeutics Corp. (BCTX)$0.037B
PMGC Holdings Inc. (ELAB)United States$0.037B
FILANA THERAPEUTICS, INC. (FLNA)United States$0.038B-1.05